Elucidating the impact of obesity on hormonal and metabolic perturbations in polycystic ovary syndrome phenotypes in Indian women
- PMID: 33635862
- PMCID: PMC7909663
- DOI: 10.1371/journal.pone.0246862
Elucidating the impact of obesity on hormonal and metabolic perturbations in polycystic ovary syndrome phenotypes in Indian women
Abstract
Polycystic ovary syndrome is a complex endocrinopathy with heterogeneous presentation and multifactorial etiology. We have undertaken this case-control study to compare metabolic and endocrine characteristics in different phenotypic subgroups of women with PCOS and the impact of obesity on them. Women with PCOS (n = 489) were classified into 4 phenotypes according to Rotterdam criteria. Comparisons of clinical, biochemical and hormonal parameters were performed across all phenotypic groups of PCOS and with controls (n = 270) by Welch's ANOVA with subsequent Games-Howell post-hoc test. We found maximum prevalence of normoandrogenic phenotype D, which is milder form of PCOS in terms of insulin resistance, gonadotropin levels and dyslipidemia, followed by phenotype A, in our total study population. After classification of the study group into lean and obese groups, only few insulin and lipid-related traits showed marked differences between phenotypes. Further, we noted that obese women showed adverse metabolic but not androgenic traits compared to lean counterparts in the same phenotype. Metabolic syndrome frequency is increased in hyperandrogenic phenotypes with HDL-C and waist circumference being most predominant contributing factors in total, lean and obese groups. We demonstrate that in our study population there is greater occurrence of phenotype D of PCOS. Our study highlights the importance of clinicians concurrently employing Rotterdam criteria along with obesity status for ascertaining accurate PCOS status and formulating suitable therapeutic intervention.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures

Similar articles
-
Increased chemerin serum levels in hyperandrogenic and normoandrogenic women from Argentina with polycystic ovary syndrome.Gynecol Endocrinol. 2020 Dec;36(12):1057-1061. doi: 10.1080/09513590.2020.1769061. Epub 2020 Jun 4. Gynecol Endocrinol. 2020. PMID: 32496833
-
Are serum chemerin levels different between obese and non-obese polycystic ovary syndrome women?Gynecol Endocrinol. 2016;32(1):38-41. doi: 10.3109/09513590.2015.1075501. Epub 2015 Aug 18. Gynecol Endocrinol. 2016. PMID: 26291816
-
Metabolic risk assessment of Indian women with polycystic ovarian syndrome in relation to four Rotterdam criteria based phenotypes.Eur J Obstet Gynecol Reprod Biol. 2018 May;224:60-65. doi: 10.1016/j.ejogrb.2018.02.031. Epub 2018 Mar 1. Eur J Obstet Gynecol Reprod Biol. 2018. PMID: 29550643
-
Metabolic syndrome and its components in different phenotypes of polycystic ovary syndrome.Diabetes Metab Res Rev. 2022 Jan;38(1):e3464. doi: 10.1002/dmrr.3464. Epub 2021 May 14. Diabetes Metab Res Rev. 2022. PMID: 33988288 Review.
-
Metabolic effect of obesity on polycystic ovary syndrome in adolescents: a meta-analysis.J Obstet Gynaecol. 2017 Nov;37(8):1036-1047. doi: 10.1080/01443615.2017.1318840. Epub 2017 Jun 28. J Obstet Gynaecol. 2017. PMID: 28657375 Review.
Cited by
-
PCOS phenotype focus: phenotype D under the magnifying glass.Arch Gynecol Obstet. 2024 Jun;309(6):2307-2313. doi: 10.1007/s00404-024-07408-2. Epub 2024 Mar 19. Arch Gynecol Obstet. 2024. PMID: 38502188 Review.
-
Role of Granulosa Cell Dysfunction in Women Infertility Associated with Polycystic Ovary Syndrome and Obesity.Biomolecules. 2025 Jun 24;15(7):923. doi: 10.3390/biom15070923. Biomolecules. 2025. PMID: 40723795 Free PMC article. Review.
-
Clinical-exome sequencing unveils the genetic landscape of polycystic ovarian syndrome (PCOS) focusing on lean and obese phenotypes: implications for cost-effective diagnosis and personalized treatment.Sci Rep. 2024 Oct 18;14(1):24468. doi: 10.1038/s41598-024-75719-0. Sci Rep. 2024. PMID: 39424910 Free PMC article.
-
Mitochondrial Dysfunction and Chronic Inflammation in Polycystic Ovary Syndrome.Int J Mol Sci. 2021 Apr 10;22(8):3923. doi: 10.3390/ijms22083923. Int J Mol Sci. 2021. PMID: 33920227 Free PMC article. Review.
-
Therapeutic effects of aqueous extract of bioactive active component of Ageratum conyzoides on the ovarian-uterine and hypophysis-gonadal axis in rat with polycystic ovary syndrome: Histomorphometric evaluation and biochemical assessment.Metabol Open. 2022 Jul 20;15:100201. doi: 10.1016/j.metop.2022.100201. eCollection 2022 Sep. Metabol Open. 2022. PMID: 35958118 Free PMC article.
References
-
- Mukherjee S, Maitra A. Molecular & genetic factors contributing to insulin resistance in polycystic ovary syndrome. The Indian journal of medical research. 2010;131:743–60. Epub 2010/06/24. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical